Concepts (137)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 16 | 2025 | 1306 | 2.730 |
Why?
|
| Memory, Short-Term | 8 | 2019 | 137 | 2.220 |
Why?
|
| Attention | 4 | 2019 | 191 | 1.420 |
Why?
|
| Mathematics | 5 | 2016 | 71 | 1.360 |
Why?
|
| Neuropsychological Tests | 15 | 2024 | 953 | 1.100 |
Why?
|
| Cognition Disorders | 5 | 2020 | 552 | 1.030 |
Why?
|
| Mutism | 2 | 2024 | 29 | 0.990 |
Why?
|
| Proton Therapy | 3 | 2022 | 155 | 0.970 |
Why?
|
| Cerebellar Neoplasms | 3 | 2024 | 316 | 0.930 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 6 | 2024 | 870 | 0.870 |
Why?
|
| Mathematical Concepts | 2 | 2015 | 7 | 0.870 |
Why?
|
| Cancer Survivors | 4 | 2025 | 273 | 0.850 |
Why?
|
| Memory Disorders | 2 | 2018 | 190 | 0.830 |
Why?
|
| Cognition | 6 | 2022 | 817 | 0.810 |
Why?
|
| Adaptation, Psychological | 2 | 2024 | 429 | 0.790 |
Why?
|
| Medulloblastoma | 2 | 2024 | 376 | 0.770 |
Why?
|
| Learning | 2 | 2018 | 353 | 0.760 |
Why?
|
| Spinal Dysraphism | 4 | 2015 | 255 | 0.730 |
Why?
|
| Survivors | 5 | 2022 | 345 | 0.690 |
Why?
|
| Reading | 5 | 2016 | 75 | 0.680 |
Why?
|
| Meningomyelocele | 2 | 2015 | 254 | 0.610 |
Why?
|
| Suicidal Ideation | 1 | 2022 | 248 | 0.600 |
Why?
|
| Child | 31 | 2025 | 26179 | 0.590 |
Why?
|
| Child Behavior Disorders | 1 | 2019 | 72 | 0.590 |
Why?
|
| Radiotherapy Dosage | 2 | 2025 | 217 | 0.580 |
Why?
|
| Developmental Disabilities | 4 | 2019 | 782 | 0.570 |
Why?
|
| Cranial Irradiation | 1 | 2018 | 71 | 0.530 |
Why?
|
| Social Class | 1 | 2019 | 212 | 0.530 |
Why?
|
| Space Perception | 2 | 2014 | 50 | 0.500 |
Why?
|
| Craniospinal Irradiation | 3 | 2023 | 58 | 0.500 |
Why?
|
| Memory | 1 | 2018 | 306 | 0.460 |
Why?
|
| Adolescent | 19 | 2025 | 20808 | 0.460 |
Why?
|
| Motor Skills | 1 | 2015 | 72 | 0.440 |
Why?
|
| Verbal Learning | 3 | 2022 | 67 | 0.420 |
Why?
|
| Visual Perception | 1 | 2014 | 127 | 0.380 |
Why?
|
| Child, Preschool | 13 | 2025 | 15005 | 0.360 |
Why?
|
| Male | 27 | 2025 | 64392 | 0.350 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 2 | 2017 | 246 | 0.340 |
Why?
|
| Female | 27 | 2025 | 70258 | 0.330 |
Why?
|
| Parents | 1 | 2017 | 1117 | 0.290 |
Why?
|
| Goals | 1 | 2010 | 126 | 0.290 |
Why?
|
| Humans | 34 | 2025 | 130104 | 0.290 |
Why?
|
| Dyslexia | 1 | 2009 | 30 | 0.290 |
Why?
|
| Brain Injuries | 1 | 2012 | 703 | 0.260 |
Why?
|
| Brain | 3 | 2025 | 3146 | 0.240 |
Why?
|
| Protons | 2 | 2022 | 94 | 0.230 |
Why?
|
| Organs at Risk | 1 | 2025 | 48 | 0.230 |
Why?
|
| Depression | 2 | 2025 | 1312 | 0.220 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2024 | 73 | 0.190 |
Why?
|
| Longitudinal Studies | 4 | 2016 | 1483 | 0.190 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2024 | 195 | 0.190 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2022 | 42 | 0.180 |
Why?
|
| Problem Solving | 3 | 2013 | 61 | 0.180 |
Why?
|
| Methotrexate | 1 | 2024 | 348 | 0.180 |
Why?
|
| Survivorship | 1 | 2022 | 45 | 0.180 |
Why?
|
| Sleep Wake Disorders | 2 | 2021 | 202 | 0.180 |
Why?
|
| Achievement | 2 | 2013 | 32 | 0.170 |
Why?
|
| Cerebellar Diseases | 1 | 2022 | 78 | 0.170 |
Why?
|
| Cognitive Dysfunction | 2 | 2023 | 336 | 0.170 |
Why?
|
| Emotions | 1 | 2024 | 349 | 0.170 |
Why?
|
| Language Development Disorders | 1 | 2022 | 176 | 0.160 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2023 | 211 | 0.160 |
Why?
|
| Neuropsychology | 1 | 2020 | 25 | 0.160 |
Why?
|
| Pain | 1 | 2022 | 430 | 0.150 |
Why?
|
| Follow-Up Studies | 4 | 2025 | 5170 | 0.150 |
Why?
|
| Neurocognitive Disorders | 1 | 2019 | 74 | 0.150 |
Why?
|
| Anxiety | 1 | 2025 | 1007 | 0.140 |
Why?
|
| Relative Biological Effectiveness | 1 | 2018 | 9 | 0.140 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2018 | 61 | 0.140 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 221 | 0.140 |
Why?
|
| Combined Modality Therapy | 2 | 2019 | 1214 | 0.140 |
Why?
|
| Transition to Adult Care | 1 | 2020 | 131 | 0.140 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2019 | 156 | 0.140 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2020 | 286 | 0.140 |
Why?
|
| Cisplatin | 1 | 2019 | 274 | 0.130 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2018 | 155 | 0.130 |
Why?
|
| Hippocampus | 2 | 2025 | 793 | 0.130 |
Why?
|
| Models, Psychological | 2 | 2020 | 138 | 0.130 |
Why?
|
| Down Syndrome | 1 | 2020 | 233 | 0.130 |
Why?
|
| Tumor Burden | 1 | 2018 | 237 | 0.130 |
Why?
|
| Organ Size | 1 | 2018 | 408 | 0.130 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2018 | 387 | 0.130 |
Why?
|
| Risk Factors | 2 | 2022 | 10955 | 0.120 |
Why?
|
| Glioma | 1 | 2021 | 495 | 0.120 |
Why?
|
| Fatigue | 3 | 2022 | 191 | 0.120 |
Why?
|
| Educational Status | 1 | 2016 | 276 | 0.110 |
Why?
|
| Prevalence | 1 | 2022 | 2687 | 0.110 |
Why?
|
| Neuroimaging | 1 | 2018 | 380 | 0.110 |
Why?
|
| Postoperative Complications | 2 | 2024 | 3113 | 0.110 |
Why?
|
| Analysis of Variance | 2 | 2013 | 929 | 0.100 |
Why?
|
| Pattern Recognition, Visual | 1 | 2013 | 22 | 0.100 |
Why?
|
| Concept Formation | 1 | 2013 | 27 | 0.100 |
Why?
|
| Prognosis | 4 | 2025 | 4857 | 0.100 |
Why?
|
| Comprehension | 1 | 2013 | 80 | 0.100 |
Why?
|
| Bone Diseases | 1 | 2012 | 48 | 0.090 |
Why?
|
| Orthopedics | 1 | 2012 | 77 | 0.090 |
Why?
|
| Antineoplastic Agents | 2 | 2019 | 1802 | 0.090 |
Why?
|
| Child Development | 1 | 2013 | 267 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 3743 | 0.060 |
Why?
|
| Retrospective Studies | 2 | 2025 | 17548 | 0.060 |
Why?
|
| Frontal Lobe | 1 | 2025 | 110 | 0.050 |
Why?
|
| Intelligence | 1 | 2023 | 101 | 0.050 |
Why?
|
| Time Factors | 1 | 2012 | 6171 | 0.050 |
Why?
|
| Intelligence Tests | 1 | 2022 | 61 | 0.050 |
Why?
|
| Social Adjustment | 1 | 2022 | 77 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2010 | 3025 | 0.040 |
Why?
|
| Young Adult | 3 | 2020 | 9990 | 0.040 |
Why?
|
| Adult | 2 | 2019 | 31022 | 0.040 |
Why?
|
| Executive Function | 1 | 2021 | 122 | 0.040 |
Why?
|
| Thyroid Diseases | 1 | 2020 | 26 | 0.040 |
Why?
|
| Age Factors | 2 | 2021 | 2822 | 0.040 |
Why?
|
| Research | 1 | 2022 | 264 | 0.040 |
Why?
|
| Professional Role | 1 | 2020 | 78 | 0.040 |
Why?
|
| Syndrome | 1 | 2022 | 1157 | 0.040 |
Why?
|
| Photic Stimulation | 1 | 2019 | 226 | 0.030 |
Why?
|
| Sleep | 1 | 2021 | 369 | 0.030 |
Why?
|
| Psychomotor Performance | 1 | 2019 | 172 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2025 | 3351 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2022 | 1440 | 0.030 |
Why?
|
| Lung Diseases | 1 | 2020 | 397 | 0.030 |
Why?
|
| Recurrence | 1 | 2020 | 1475 | 0.030 |
Why?
|
| Metabolomics | 1 | 2020 | 501 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2023 | 1826 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 1240 | 0.030 |
Why?
|
| Phonetics | 1 | 2013 | 24 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 1282 | 0.020 |
Why?
|
| Reaction Time | 1 | 2013 | 151 | 0.020 |
Why?
|
| Epilepsy | 1 | 2020 | 864 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2023 | 3406 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2020 | 5038 | 0.020 |
Why?
|
| Biomarkers | 1 | 2020 | 3355 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 3777 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2011 | 242 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2020 | 6397 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2011 | 759 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 2094 | 0.020 |
Why?
|
| Infant | 1 | 2021 | 13264 | 0.010 |
Why?
|